Data in brief 25 (2019) 104311



Contents lists available at ScienceDirect

Data in brief

journal homepage: www.elsevier.com/locate/dib

Data Article

Effect of parental origin of damaging variants in pro-angiogenic genes on fetal growth in patients with congenital heart defects: Data and analyses



Mark W. Russell ^{a, *}, Julie S. Moldenhauer ^b, Jack Rychik ^c, Nancy B. Burnham ^d, Erin Zullo ^d, Samuel I. Parry ^e, Rebecca A. Simmons ^f, Michal A. Elovitz ^e, Susan C. Nicolson ^g, Rebecca L. Linn ^h, Mark P. Johnson ^b, Sunkyung Yu ^a, Matthew G. Sampson ^{i, j}, Hakon Hakonarson ^k, J. William Gaynor ^d

^a Division of Pediatric Cardiology, Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI, USA

^b Center for Fetal Diagnosis and Therapy, The Children's Hospital of Philadelphia, Philadelphia, PA, USA

^c Division of Pediatric Cardiology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA

^d Division of Cardiothoracic Surgery, The Children's Hospital of Philadelphia, Philadelphia, PA, USA

^e Division of Maternal Fetal Medicine, Perelman School of Medicine, The University of Pennsylvania, Philadelphia, PA, USA

^f Division of Neonatology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA

^g Division of Cardiothoracic Anesthesiology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA

^h Division of Anatomic Pathology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA

¹ Division of Pediatric Nephrology, Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI, USA

^j Center for Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, USA ^k The Center for Applied Genomics, The Children's Hospital of Philadelphia and the Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

ARTICLE INFO

Article history: Received 5 June 2019

ABSTRACT

The placenta is a highly vascular structure composed of both maternal and fetal elements. We have determined that damaging

DOI of original article: https://doi.org/10.1016/j.jpeds.2019.05.013.

* Corresponding author.

E-mail addresses: mruss@med.umich.edu (M.W. Russell), moldenhauerj@email.chop.edu (J.S. Moldenhauer), rychik@email. chop.edu (J. Rychik), BURNHAMN@email.chop.edu (N.B. Burnham), WehrungE1@email.chop.edu (E. Zullo), parry@pennmedicine.upenn.edu (S.I. Parry), rsimmons@pennmedicine.upenn.edu (R.A. Simmons), melovitz@obgyn.upenn.edu (M.A. Elovitz), nicolson@email.chop.edu (S.C. Nicolson), Linnr@email.chop.edu (R.L. Linn), johnsonma@email.chop.edu (M.P. Johnson), skyu@ med.umich.edu (S. Yu), mgsamps@med.umich.edu (M.G. Sampson), hakonarson@email.chop.edu (H. Hakonarson), GAYNOR@ email.chop.edu (J.W. Gaynor).

https://doi.org/10.1016/j.dib.2019.104311

2352-3409/© 2019 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).

Received in revised form 14 July 2019 Accepted 17 July 2019 Available online 26 July 2019

Keywords: Genetic variation Placental function Fetal growth Congenital cardiac defects variants in genes responsible for the positive regulation of angiogenesis (PRA) (GO:0045766) that are inherited by the fetus impair fetal growth and placental function in pregnancies involving critical congenital cardiac defects (Russell et al., 2019). In this dataset, we present the specific genetic variants identified, describe the parental origin of each variant where possible and present the analyses regarding the potential effects of parental origin of the variant on placental function and fetal growth. The data presented are related to the research article "Damaging variants in proangiogenic genes impair growth in fetuses with cardiac defects" (Russell et al., 2019).

© 2019 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/ licenses/by-nc-nd/4.0/).

Specifications Table

| Subject area | Biology |
|----------------------------|--|
| More specific subject area | Molecular Genetics |
| Type of data | Tables |
| How data was acquired | Whole exome sequencing was performed as described in the related research article [1]. Exons |
| | were captured from fragmented and adaptor ligated genomic DNA samples using the SureSelect |
| | Human All Exon v.5 containing 51 Mb (Agilent Technologies, Santa Clara, CA). Paired-end |
| | 2x101-base massively parallel sequencing was carried out on the Illumina HiSeq2500 platform |
| | (Illumina, San Diego, CA), according to the manufacture's protocols. Base calling was performed |
| | by the Illuming (ASAVA software (version 1.8.2) with default parameters |
| Data format | Analyzed |
| Experimental factors | Sequencing reads were aligned to the human reference genome (GRCh37-derived alignment set |
| Experimental factors | used in 1000 Cenomes Project) and the Cenome Analysis Toolkit (CATK v 26-5) was used to |
| | agenerate variant calls as previously described [1] |
| Experimental features | Eamilies delivering a haby with a congenital heart defact (CHD) requiring surgical repair in |
| Experimental leatures | information under segmitted for the study. Europingental mathematic under under segmitted in the related |
| | injuncy were recruited for the study. Experimental methods were described in the related |
| | research article. Briejly, |
| | (1) The placenta and neonate were weighed and measured. |
| | (ii) Exome sequencing was performed on the subjects ($N = 133$) and their parents ($N = 114$ |
| | parent-child trios and 15 parent-child duos). |
| | (111) The GeneVetter analysis tool (default settings) was used to identify damaging coding |
| | sequence variants in genes identified as positive regulators of angiogenesis (PRA) (GO:0045766). |
| | (iv) The effect of inherited and not inherited parental damaging PRA variants on placental |
| | function and fetal growth were examined. |
| Data source location | Data source: Division of Cardiothoracic Surgery, The Children's Hospital of Philadelphia, |
| | Philadelphia, PA |
| | Data analysis: Division of Pediatric Cardiology, Department of Pediatrics, University of Michigan |
| | Medical School, Ann Arbor, MI |
| Data accessibility | All of the data is presented in this article. The subjects were not consented for the raw sequence |
| | data to be released to a public database so what is presented is the analyzed and summarized |
| | data. |
| Related research article | M.W. Russell, J.S. Moldenhauer, J. Rychik, N.B. Burnham, E. Zullo, S.I. Parry, R.A. Simmons, M.A. |
| | Elovitz, S.C. Nicolson, R.L. Linn, M.P. Johnson, S. Yu, M.G. Sampson, H. Hakonarson, J.W. Gaynor. |
| | Damaging variants in pro-angiogenic genes impair growth in fetuses with cardiac defects. |
| | Pediatr. 2019 Jun 18; https://doi.org/10.1016/j.jpeds.2019.05.013. [Epub ahead of print] |
| | PubMed PMID: 31227283. |
| | |

Value of the data

- The presented data will facilitate the evaluation of fetal and maternal genetic variation on placental function and fetal growth in pregnancies involving a fetus with a CHD.
- The data will directly benefit investigators examining the relationship between fetal growth and development and clinical outcomes in infants with critical CHD.
- In the accompanying tables, different ways of grouping the data are used to examine the effects of inherited and not inherited genetic variation on placental function and fetal growth. The value of the data will be in the stimulation of ideas and approaches to estimate these complex genetic relationships.
- Of particular interest is the potential interaction effect of damaging PRA variants present in both the mother and fetus. The
 interaction effect will require a much larger cohort to adequately assess; the presentation of the aggregate data using
 several different approaches will allow merging of the data with that from ongoing and future efforts.

1. Data

We performed exome sequencing on infants with critical congenital heart disease (N = 133) and their parents (N = 114 parent-child trios and 15 parent-child duos). Using the GeneVetter program, we

Table 1

Positive Regulation of Angiogenesis (PRA) gene set (GO:0045766).

| Positive Regulation of Angiogenesis (PRA) | | | | | | |
|---|---------|----------|----------|--|--|--|
| ABL1 | CX3CR1 | HSPB1 | PTGS2 | | | |
| ACVRL1 | CXCL8 | HSPB6 | PTK2B | | | |
| ADAM12 | CXCR2 | HYAL1 | RAMP2 | | | |
| ADM | CYBB | IL10 | RAPGEF3 | | | |
| ADM2 | CYP1B1 | IL1A | RHOB | | | |
| AGGF1 | CYSLTR2 | IL1B | RHOJ | | | |
| AGO2 | DDAH1 | ISL1 | RLN2 | | | |
| AGTR1 | DLL1 | ITGA5 | RRAS | | | |
| АКТЗ | ECM1 | ITGB1 | RUNX1 | | | |
| ANGPT2 | Emilin2 | ITGB2 | S100A1 | | | |
| ANGPT4 | ENG | ITGB8 | SASH1 | | | |
| ANGPTL3 | EPHA1 | JAK1 | SEMA5A | | | |
| ANGPTL4 | ERAP1 | JCAD | SERPINE1 | | | |
| ANXA1 | ETS1 | IUP | SFRP2 | | | |
| ANXA3 | F3 | KDR | SIRT1 | | | |
| APELA | FGF1 | KLF4 | SIRT6 | | | |
| APLNR | FGF18 | LRG1 | SMAD1 | | | |
| AQP1 | FGF2 | MAP3K3 | SMOC2 | | | |
| BMPER | FGFBP1 | MTDH | SP1 | | | |
| BRCA1 | FLT1 | MYDGF | SPHK1 | | | |
| BTG1 | FOXC2 | NFE2L2 | SRPX2 | | | |
| C3 | GAB1 | NODAL | STAT3 | | | |
| C3AR1 | GATA2 | NOS3 | STIM1 | | | |
| C5 | GATA4 | NR2E1 | TBXA2R | | | |
| C5AR1 | GATA6 | NRP1 | TEK | | | |
| C6 | GDF2 | PAK4 | TN-W | | | |
| CCBE1 | GHRL | PDCD6 | TERT | | | |
| CCL11 | GHSR | PDCL3 | TGFBR2 | | | |
| CCL24 | GREM1 | PDPK1 | THBS1 | | | |
| CCR3 | HDAC7 | PGF | TLR3 | | | |
| CD34 | HDAC9 | PIK3C2A | TMIGD2 | | | |
| CD40 | HGF | PIK3R6 | TNFSF12 | | | |
| CDH5 | HIF1A | PLCG1 | TWIST1 | | | |
| CELA1 | HIPK1 | PLK2 | UTS2R | | | |
| CHI3L1 | HIPK2 | PPP1R16B | VASH2 | | | |
| CHRNA7 | HK2 | PRKCA | VEGFA | | | |
| CIB1 | HMGA2 | PRKCB | VEGFB | | | |
| CMA1 | HMGB1 | PRKD1 | VEGFC | | | |
| CTSH | HMOX1 | PRKD2 | VEGFD | | | |
| CX3CL1 | HPSE | PTGIS | WNT5A | | | |
| | | | XBP1 | | | |
| | | | ZC3H12A | | | |
| | | | ZNF304 | | | |
| | | | | | | |

Table 2

Sequence variants identified as damaging by GeneVetter analysis in the 163 positive regulator of angiogenesis (PRA) genes (GO:0045766) in the cohort.

| Subject id | gene | chr:pos:ref:alt | id | aa change |
|------------|---------|------------------------------------|----------------------------|------------------|
| C57 | ABL1 | 9:133738189:G:A | 3738189:G:A rs150134901 | |
| C1 | ADAM12 | 10:127738138:G:C | | C573W |
| C17 | ADAM12 | 10:127737958:T:C | rs77297117 | N597S |
| C135 | ADAM12 | 10:127737958:T:C | rs77297117 | N597S |
| C44 | ANGPT2 | 8:6371240:C:G | rs149383060 | L386F |
| C84 | ANGPT2 | 8:6371240:C:G | rs149383060 | L386F |
| C59 | ANXA3 | 4:79522685:C:T | rs5949 | P251L |
| C87 | AOP1 | 7:30961780:C:T | | R222C |
| C120 | AOP1 | 7:30961753:G:A | rs200906195 | V213M |
| C73 | BRCA1 | 17:41246709:G:C | rs80357199 | A280G |
| C121 | BRCA1 | 17:41243948:C:G | | 01200H |
| C44 | BRCA1 | 17:41256200:C:A | | S127I |
| C95 | C3 | 19:6693489:T·A | · | 010551 |
| C47 | G | 19:6686180:C:G | rs371629277 | W1255C |
| C132 | 6 | 5:41203257:C:T | 1337 1023277 | H26N |
| C66 | C6 | 5:41150035:A·C | rs76202909 | 112011 |
| C134 | C6 | 5:41150035:A.G | rs76202909 | |
| C05 | CCBE1 | 18:57364474:C·T | rs101000071 | T34N |
| C35 | CCP2 | 2.46207212.4.C | rc129246210 | 1341 |
| C20 | CCP2 | 2.46207212.A.C | rc128246210 | 12431 |
| C131 | CCR2 | 3.40307313.A.G | 15136340219 | 1245 V |
| C152 | CCR3 | 3.40300043.C.1 | 15201795127 | KO/A |
| C46 | CCR3 | 3:46307064:G:A | 15145141172 | V I OUIVI |
| C5 | CD34 | 1:208084424:A:G | rs370283469 | MII |
| C89 | CD34 | 1:208072436:G:A | rs148688256 | 11331 |
| C135 | CD34 | 1:208072436:G:A | rs148688256 | 11331 |
| C56 | CDH5 | 16:66420973:G:A | | A1581 |
| C51 | CDH5 | 16:66436582:G:A | rs139612718 | R622Q |
| C44 | CHI3L1 | 1:203152888:G:A | rs199779694 | R116C |
| C39 | CHI3L1 | 1:203154465:C:T | rs146010120 | R35Q |
| C128 | CHI3L1 | 1:203154468:T:C | • | Y34C |
| C112 | CHRNA7 | 15:32393507:A:T | • | D95V |
| C15 | CHRNA7 | 15:32450712:A:G | rs142728508 | Y262C |
| C125 | CIB1 | 15:90774612:G:A | • | S108F |
| C129 | CTSH | 15:79224791:C:T | | G139S |
| C28 | CYP1B1 | 2:38298338:C:T | | E387K |
| C48 | CYP1B1 | 2:38298028:T:A | | Q490L |
| C108 | CYP1B1 | 2:38298028:T:A | | Q490L |
| C1 | CYP1B1 | 2:38302045:G:A | rs104894978 | R163C |
| C90 | CYP1B1 | 2:38301574:C:A | rs72549382 | V320L |
| C70 | CYP1B1 | 2:38297867:A:T | rs368552668 | X544K |
| C70 | EMILIN2 | 18:2913203:A:T | | E988V |
| C89 | EMILIN2 | 18:2913098:T:A | | L953Q |
| C65 | EPHA1 | 7:143092241:C:A | | E706D |
| C30 | EPHA1 | 7:143095083:T:G | _ | R515S |
| C13 | EPHA1 | 7:143095862:C:T | | V390M |
| C18 | ETS1 | 11:128354768:T:C | | K271R |
| C40 | FGF1 | 5·141993631·C·T | rs17223632 | G21E |
| C67 | FGF1 | 5:141993631:C·T | rs17223632 | G21E |
| C66 | FGF18 | 5:170883784·C·A | rs371575721 | R2000 |
| C68 | FIT1 | 13·28919631·C·A | rs200840674 | A769V |
| C12 | | 12.20212021.G.A | 15200040074 | D12011 |
| C13 C91 | | 13.20003/0U.G.A | 15140001115 rc140961115 | F12UIL D12011 |
| C75 | FOVCO | 15.20003/00.G.A 16.96603422.T.C | 15140001115 | CADOD |
| C/5 | FUXC2 | 10:80002433:1:0 | 1501/03340 | C498K |
| C30 | FUXC2 | 10:800U2272:A:G | rs14/258453 | Q444K |
| (3/ | GABI | 4:144359333:1:C | rs201252337 | Y259H |
| C/5 | GDF2 | 10:48414216:C:T | rs142402214 | D218N |

Table 2 (continued)

| Subject id | gene | chr:pos:ref:alt | id | aa change |
|--------------|-------------|------------------------------------|--------------|-------------|
| C114 | GDF2 | 10:48414216:C:T | rs142402214 | D218N |
| C32 | GHRL | 3:10328465:A:G | rs376322935 | L86P |
| C120 | HDAC7 | 12:48183606:C:T | rs200899015 | R711H |
| C123 | HDAC9 | 7:18629974:C:G | | L94V |
| C89 | HGF | 7:81374380:A:C | rs139457161 | S228A |
| C133 | HIF1A | 14:62194346:A:C | rs373399672 | D273A |
| C21 | HIPK2 | 7:139285223:C:T | rs56132157 | R792Q |
| C89 | HK2 | 2:75105946:C:T | | A388V |
| C129 | HK2 | 2:75113788:C:T | rs146476722 | P736L |
| C115 | HK2 | 2:75106029:G:A | | V416I |
| C134 | HPSE | 4:84243462:C:T | | G95S |
| C5 | HPSE | 4:84216649:G:A | rs144185023 | Q494X |
| C140 | HPSE | 4:84216649:G:A | rs144185023 | Q494X |
| C26 | HSPB1 | 7:75932109:G:C | rs367662394 | R27P |
| C103 | HYAL1 | 3:50338090:C:T | | A378T |
| C124 | HYAL1 | 3:50339969:T:C | | N140S |
| C37 | IL1A | 2:113541307:C:G | rs150033245 | C14S |
| C9 | ITGB2 | 21:46308800:C:T | rs2230531 | E630K |
| C139 | ITGB2 | 21:46308800:C:T | rs2230531 | E630K |
| C140 | ITGB2 | 21:46308800:C:T | rs2230531 | E630K |
| C73 | JUP | 17:39925401:C:T | rs144171604 | R176Q |
| C12 | KLF4 | 9:110249816:G:A | rs139237114 | H287Y |
| C137 | MAP3K3 | 17:61767648:G:A | | R394H |
| C120 | NFE2L2 | 2:178096406:G:A | rs141363120 | L309F |
| C44 | NOS3 | 7:150693897:G:A | rs141456642 | E156K |
| C137 | NOS3 | 7:150693897:G:A | rs141456642 | E156K |
| C132 | NOS3 | 7:150706545:C:T | rs368180942 | P795L |
| C16 | NOS3 | 7:150709452:C:T | | R1000W |
| C55 | NOS3 | 7:150707257:G:A | rs201579252 | R856H |
| C18 | NRP1 | 10:33515198:C:T | | R334H |
| C62 | PAK4 | 19:39668385:C:G | | P519R |
| C52 | PAK4 | 19:39666005:C:T | rs377696830 | S429L |
| C89 | PDPK1 | 16:2627442:C:G | | F242L |
| C109 | PIK3C2A | 11:17150917:C:T | rs149664988 | D777N |
| C115 | PIK3C2A | 11:17172056:A:G | rs138300747 | F439S |
| C32 | PIK3C2A | 11:17191207:1:C | rs142132566 | K28E |
| C94 | PIK3C2A | 11:17140241:G:A | | L996F |
| C60 | PIK3C2A | 11:17126742:1:C | | N1219D |
| C68 | PIK3C2A | 11:1/150848:G:A | rs201036447 | R800W |
| C5 | PLCGI | 20:39801462:A:1 | rs14/844565 | D1075V |
| C27 | PLK2 | 5:57755583:C:A | rs3/2211010 | E68D |
| C4 | PKKDI | 14:30390099:A:G | | L/P DO1C |
| C96 | PIGIS | 20:48104484:G:A | 18200631702 | RUIC |
| C40 | PIG52 | 1:180048228:G:A | | P92L |
| C93 | RAPGEF3 | 12:48137442:G:A | 15200527655 | KOODVV |
| C112 C128 | RAPGEF3 | 12:48131987:C:1 | 15200517997 | 5857IN |
| C138 | RAPGERS | 12:48141598:1:0 | 15140484121 | 1457C |
| C44 C100 | RIO | 14.03749908.G.A | 15150545066 | EIJOK |
| C100 | | 14.05/4/854.G.1 | 153/24/2306 | B10900 |
| C15 C111 | 5A5H1 | 6.148865872.C.A | rc751/0215 | R10890 |
| C111 C122 | | 0.1400000/2.G.A 6.140067017.C.T | 1575149515 | R1009Q |
| C104 | 5A5H1 | 6.148860462.0.4 | rs1/2577116 | R1139W |
| C104 C115 | SERDINE1 | 7.100780350.C.T | 131-133//110 | R386W/ |
| C115 C43 | SERFINE I | 12:53776845:00 | • | 0372F |
| C+5 C100 | JI'I TEK | 0.27160568.C.T | • | (10012E |
| C100 | LITCOD | 3.27103306.C.I 17.902227490.C.A | rc201062255 | DOZN |
| | 0132K | 17.00332409.G.A | 15201905255 | DALM |

Chr:pos:ref:alt: (Chromosome:position:reference nucleotide; "altered" or substituted nucleotide) refers to the location of the genetic alteration with the position referring to the GRCh37/hg19 Assembly.

Table 3

Effect of parental damaging PRA variants on placental function and fetal growth. The data is evaluated from the fetal perspective. For example, for the question, "Was there a variant in the father that was inherited by the infant?", the "No" answer will include cases in which the father had no variants and cases in which the father did have a variant but it wasn't inherited by the proband.

| | | Available N | Weight z-score | Height z-score | Head circumference z-score | UA PI z-score |
|--|-----------|---------------------|--|--|--|---|
| Was there a variant in the father that was inherited by the infant? | Yes No | 41 72 P-value | -0.11 ± 0.92 0.01 ± 0.88 0.53 | -0.12 ± 1.3 -0.04 ± 1.4 0.77 | -0.51 ± 1.1 -0.13 ± 1.2 0.10 | 1.28 ± 1.3 0.79 ± 1.4 0.11 |
| Was there a variant in the father that wasn't inherited by the infant? | Yes No | 46 64 P-value | $\begin{array}{c} 0.05 \pm 0.87 \\ -0.10 \pm 0.92 \\ 0.40 \end{array}$ | -0.07 ± 1.2 -0.06 ± 1.4 0.97 | -0.12 ± 1.1 -0.40 ± 1.3 0.22 | 0.82 ± 1.3 0.99 ± 1.4 0.59 |
| Was there a variant in the mother that was inherited by the infant? | Yes No | 40 88 P-value | -0.34 ± 0.89 0.01 ± 0.95 0.053 | -0.60 ± 1.3 0.05 ± 1.5 0.02 | -0.67 ± 1.1 -0.12 ± 1.2 0.01 | 1.08 ± 1.3 0.80 ± 1.4 0.34 |
| Was there a variant in the mother that wasn't inherited by the infant? | Yes No | 47 81 P-value | $\begin{array}{c} 0.04 \pm 0.89 \\ -0.18 \pm 0.97 \\ 0.19 \end{array}$ | $\begin{array}{c} 0.04 \pm 1.5 \\ -0.27 \pm 1.4 \\ 0.26 \end{array}$ | -0.26 ± 1.1 -0.31 ± 1.2 0.79 | $\begin{array}{c} 0.86 \pm 1.4 \\ 0.92 \pm 1.3 \\ 0.83 \end{array}$ |

* Data are presented as Mean \pm Standard deviation.

[§] P-value from two-sample t-test.

identified 113 pathogenic variants in the 163 positive regulators of angiogenesis (PRA) genes (Table 1) in 73 subjects (see Table 2 for specific variants identified in the probands). To estimate the effects of the parental damaging PRA variants on placental function and fetal growth, we grouped the data to examine the effects from different perspectives. First, we examined the effects from the fetal perspective to assess whether a variant inherited or not inherited from either parent had an effect on placental function and fetal growth (Table 3). To remove the effects of having variants in both parents, we next restricted analysis to those cases where only a single parent had identified pathogenic variants (Table 4). Lastly, to specifically assess the effects of maternal variants on placental function and fetal growth, we grouped all cases based on the presence or absence of maternal variants that were inherited or not inherited and not inherited variants on placental function and fetal growth in pregnancies involving CHD. In addition, it is anticipated that the different approaches to grouping the

Table 4

Effect of parental origin of damaging PRA variants on placental function and fetal growth. The data only includes those cases in which inherited variants or not inherited variants originate from a single parent. For example, for the question, "Was there a variant in the father that was inherited by the infant?", the "Yes" answer includes only those cases in which one or more variants were inherited from the father and no variants were inherited from the mother. Similarly, for the question, "Was there a variant in the father that wasn't inherited by the infant?", only those cases in which no PRA variant was noted in the proband <u>and</u> there were 1 or more variants in the father were included.

| | | Available N | Weight z-score | Height z-score | Head circumference | UA PI |
|--|-----|-------------|----------------|-----------------|--------------------|-------------|
| | | | | | z-score | z-score |
| Was there a variant in the father that was inherited by the infant? | Yes | 25 | 0.01 ± 0.97 | -0.02 ± 1.4 | -0.26 ± 1.0 | 1.36 ± 0.71 |
| Was there a variant in the mother that was inherited by the infant? | Yes | 24 | -0.37 ± 0.95 | -0.82 ± 1.4 | -0.51 ± 1.1 | 1.03 ± 0.44 |
| | | P-value | 0.17 | 0.054 | 0.41 | 0.43 |
| Was there a variant in the father that wasn't inherited by the infant? | Yes | 31 | -0.04 ± 0.85 | -0.22 ± 1.1 | -0.18 ± 1.1 | 0.58 ± 0.05 |
| Was there a variant in the mother that wasn't inherited by the infant? | Yes | 32 | -0.04 ± 0.88 | -0.06 ± 1.7 | -0.39 ± 1.2 | 0.70 ± 0.18 |
| - | | P-value | 0.97 | 0.65 | 0.48 | 0.74 |

*Data are presented as Mean ± Standard deviation.

[§] P-value from two-sample t-test.

Table 5

Effect of maternal damaging PRA variants on placental function and fetal growth. The data specifically examines the effects of maternal PRA variants. All probands with maternal data are included in the analysis. Each subject was assigned to one of the six categories based on variant distribution.

| | | Available N | Weight z-score | Height z-score | Head circumference z-score | UA PI z-score |
|------------------------------------|--------------------------------------|---------------|---------------------|---------------------|----------------------------------|--------------------|
| No damaging variant in infant | No damaging variant in mother | 37 | 0.09 ± 0.99 | 0.21 ± 1.2 | 0.14 ± 1.3 | 0.65 ± 1.4 |
| | 1 or more damaging variant in mother | 20 | 0.12 ± 0.65 | 0.27 ± 1.7 | -0.33 ± 1.0 | 0.44 ± 1.5 |
| | | P-value | 0.90 | 0.91 | 0.17 | 0.64 |
| 1 damaging variant in infant | Not inherited from mother | 25 | -0.26 ± 1.1 | -0.43 ± 1.8 | -0.29 ± 1.1 | 1.14 ± 0.97 |
| | Inherited from mother | 18 P-value | -0.14 ± 1.0 0.70 | -0.72 ± 1.5 0.58 | -0.49 ± 1.3 0.57 | 1.45 ± 1.0 0.40 |
| 2 + damaging variants in infant | None inherited from mother | 6 | -0.05 ± 1.0 | -0.03 ± 1.2 | -0.46 ± 0.90 | 1.96 ± 2.0 |
| | At least one inherited from mother | 22 | -0.42 ± 0.79 | -0.43 ± 1.1 | -0.79 ± 1.1 | 0.81 ± 1.4 |
| | | P-value | 0.35 | 0.44 | 0.50 | 0.14 |

* Data are presented as Mean ± Standard deviation.

§ P-value from two-sample t-test.

cases for analysis will help in the design and analysis of future work examining parental genetic factors impacting the maternal-fetal environment and fetal growth.

2. Experimental design, materials, and methods

For a complete description of the experimental design and methods, please see the related research article [1]. Briefly, whole exome sequencing was performed on 133 subjects and all consented parents (114 parent-child trios, 15 parent-child duos and 4 child only). Exons were captured from fragmented and adaptor ligated genomic DNA samples using the SureSelect Human All Exon v.5 containing 51 Mb (Agilent Technologies, Santa Clara, CA). Paired-end 2×101 -base massively parallel sequencing was carried out on the Illumina HiSeq2500 platform (Illumina, San Diego, CA), according to the manufacture's protocols, Base calling was performed by the Illumina CASAVA software (version 1.8.2) with default parameters. Sequencing reads passing the quality filter were aligned to the human reference genome (GRCh37-derived alignment set used in 1000 Genomes Project) with Burrows-Wheeler Aligner (BWA, v.0.7.12) and Dragen (Illumina, San Diego, CA) [2]. PCR duplicates were removed using Picard (v.1.97; Broad Institute, Boston, MA). The Genome Analysis Toolkit (GATK, v.2.6-5; Broad Institute, Boston, MA) was used to generate variant calls. The Gene Ontology (GO) database was used to identify the target gene set. The GO term "positive regulator of angiogenesis" (PRA) (GO:0045766) was selected to minimize potential opposing effects of damaging variants in positive and negative regulators. The PRA gene set contains 163 genes (Table 1). Damaging variants in the PRA gene set were identified using the GeneVetter program, a web-based analysis tool designed to improve the accuracy of pathogenicity prediction for single nucleotide variants identified by exome sequencing [3]. To be adjudicated as damaging by using the program's default settings, a variant must meet all of the following criteria: (i) have a maximum allele frequency in the sample population of <0.05, (ii) be adjudicated as "Damaging" by at least 2 of 3 of the following algorithms: PolyPhen2, SIFT, and MutationTaster, and (iii) have a maximum allele frequency across European-Americans and African-Americans of <0.005.

Acknowledgments

The authors would like to thank the patients and families that participated in this study. Supported by the Daniel M. Tabas and Alice Langdon Warner Endowed Chairs in Pediatric Cardiothoracic Surgery

and the Division of Cardiothoracic Surgery, The Children's Hospital of Philadelphia and the Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA and NIH/NCATS (National Center for Advancing Translational Sciences): Grant UL1TR000003.

Conflict of interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

- [1] M.W. Russell, J.S. Moldenhauer, J. Rychik, N.B. Burnham, E. Zullo, S.I. Parry, R.A. Simmons, M.A. Elovitz, S.C. Nicolson, R.L. Linn, M.P. Johnson, S. Yu, M.G. Sampson, H. Hakonarson, J.W. Gaynor, Damaging variants in pro-angiogenic genes impair growth in fetuses with cardiac defects, J. Pediatr. (2019 Jun 18), https://doi.org/10.1016/j.jpeds.2019.05.013. pii: S0022-3476(19)30578-5.
- [2] H. Li, R. Durbin, Fast and accurate short read alignment with Burrows-Wheeler Transform, Bioinformatics 25 (14) (2009) 1754–1760.
- [3] C.E. Gillies, C.C. Robertson, M.G. Sampson, H.M. Kang, GeneVetter: a web tool for quantitative monogenic assessment of rare diseases, Bioinformatics 31 (22) (2015) 3682–3684.